Table 1 Characteristics of patients, their disease, and treatment
Characteristic | No. of patients (%) |
|---|---|
Median age (range) | 46.5 (14–74) |
Sex | |
Male | 14 (63.6) |
Female | 8 (36.4) |
Tumor site | |
Lacrimal gland | 13 (59.1) |
Lacrimal sac | 5 (22.7) |
Orbital bone | 1 (4.5) |
Other | 3 (13.6) |
Tumor histology | |
Adenoid cystic carcinoma | 11 (50.0) |
Adenocarcinoma | 5 (22.7) |
Squamous cells carcinoma | 1 (4.5) |
Melanoma | 1 (4.5) |
rhabdomyosarcoma | 1 (4.5) |
desmoplastic small round cell tumor | 1 (4.5) |
alveolar soft part sarcoma | 1 (4.5) |
chondrosarcoma | 1 (4.5) |
T category | |
T1 | 2 (9.1) |
T2 | 7 (31.8) |
T3 | 4 (18.2) |
T4 | 9 (40.9) |
Tumor status | |
Primary | 21 (95.5) |
Recurrence | 1 (4.5) |
Surgical margin | |
R0 | 3 (13.6) |
R1 | 6 (27.3) |
R2 or biopsy | 13 (59.1) |
Interval from surgery to radiotherapy, mo | |
Median (range) | 2.2 (1.2–6.13) |
Radiotherapy technique | |
PRT | 1 (4.5) |
CIRT | 18 (81.8) |
PRT + CIRT | 3 (13.6) |
Radiotherapy dose (Gy BED) | |
Median (range) | 85.05 (67.2–94.5) |
GTV (ml) | |
Median (range) | 16.0 (1.9–67.6) |
CTV (ml) | |
Median (range) | 43.4 (18.8–209.9) |
Concurrent chemotherapy or immunotherapy | |
Cisplatin | 2 (9.1) |
Interferon α-2b | 1 (4.5) |
No | 19 (86.4) |